Non-alcoholic fatty liver disease (NAFLD) is characterized by excessive fat deposition in the liver in the absence of significant alcohol consumption. Dysregulated bile acid (BA) metabolism is an important indicator in the pathology of NAFLD, which could progress into more severe forms of liver injury. Lipid metabolism, immune environment and intestinal bacteria are all affected by dysregulated BA metabolism directly, but the mechanisms remain unclear. Several drug candidates that target BA metabolism, either used alone or in combination with other agents, are currently under development for treatment of NAFLD. Here, we summarize the relationship of dysregulated BA metabolism and NAFLD, discuss the effects and mechanisms of dysregulated BAs-induced lipid metabolism disorder. Challenges in developing novel treatments are also discussed.

非酒精性脂肪肝疾病（NAFLD）的特征是在没有大量饮酒的情况下肝脏中脂肪过多沉积。胆汁酸（BA）代谢失调是NAFLD病理学的重要指标，可能会发展为更严重的肝损伤形式。脂代谢，免疫环境和肠道细菌都直接受到BA代谢失调的直接影响，但机制尚不清楚。目前正在开发几种靶向BA代谢的候选药物，它们可以单独使用或与其他药物联合使用，以治疗NAFLD。在这里，我们总结失调的BA代谢和NAFLD的关系，讨论失调的BAs引起的脂质代谢障碍的作用和机制。还讨论了开发新疗法的挑战。